Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-DM: Toujeo in Uncontrolled T2DM
NCT03760991Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in glycated hemoglobin (HbA1c) at 26 weeks. Started Dec 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03760991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760991.